跳转至内容
Merck
CN

Does lithium carbonate therapy for alcoholism deter relapse drinking?

Recent developments in alcoholism : an official publication of the American Medical Society on Alcoholism, the Research Society on Alcoholism, and the National Council on Alcoholism (1989-01-01)
D C Clark, J Fawcett
摘要

In order to test the efficacy of lithium therapy for alcoholism, to test whether lithium therapy reduces depressive symptoms among alcoholics, and to test whether any positive lithium treatment effects are associated with an antidepressant action, we undertook a double-blind placebo-controlled study of 122 patients meeting DSM-III criteria for alcohol dependence and hospitalized for alcoholism rehabilitation. We used survival analysis to examine the cumulative proportion of each treatment group that remained abstinent (i.e., "survived") over the course of 18 months, using complete abstinence from alcohol as the principal outcome measure. Our findings add support to the hypothesis that lithium carbonate promotes abstinence from alcohol and delays the time to first drink. Patients treated with lithium were much less likely to be rehospitalized for alcoholism rehabilitation during the 18-month follow-up. These effects did not appear to be related to the treatment of concomitant or underlying affective symptoms. We found no support, on the other hand, for the hypothesis that lithium therapy reduces the frequency of drinking for relapse drinkers.

材料
产品编号
品牌
产品描述

Sigma-Aldrich
碳酸锂, ACS reagent, ≥99.0%
Sigma-Aldrich
碳酸锂, puriss. p.a., ACS reagent, ≥99.0% (T)
Sigma-Aldrich
碳酸锂, 99.999% trace metals basis
Sigma-Aldrich
碳酸锂, 99.997% trace metals basis